FDA Approves Merck's Lipfendra as First Oral PCSK9 Inhibitor

Key Facts

In a move reflecting the accelerating pace of innovation in the healthcare sector, the FDA has approved Merck's Lipfendra. This drug marks a significant milestone as the first oral PCSK9 inhibitor designed to lower LDL cholesterol. Previously, this class of treatment was exclusively available via injection, and this breakthrough is expected to drive significant market potential for Merck while boosting investor confidence in its pharmaceutical pipeline.

This approval positions Merck as a formidable competitor against peers like Amgen and Sanofi, who currently dominate the PCSK9 market with injectable therapies. Per market data and recent earnings reports, the cholesterol management market represents a multi-billion dollar opportunity; for instance, Amgen's Repatha has seen consistent revenue growth in recent quarters (per Amgen financial filings). Merck's oral alternative is expected to disrupt these dynamics by offering a more convenient administration route for patients.

Merck (MRK) shares closed at $127.63 (close July 16, 2026), after reaching a session high of $128.93. Investors are now shifting focus toward the commercial rollout strategy and its projected impact on fiscal year earnings. Looking ahead, market participants will monitor broader sentiment through upcoming central bank communications, including a scheduled speech by Fed Governor Bowman on July 14, which may influence volatility across the healthcare sector.